Stable glassy state powder formulations
AssigneeInhale Therapeutic Systems
InventorsLinda C. Foster, Mei-chang Kuo, Sheila R. Billingsley
Life of this patent
Estimating the term…
Loading patent…
AssigneeInhale Therapeutic Systems
InventorsLinda C. Foster, Mei-chang Kuo, Sheila R. Billingsley
Estimating the term…
A powdered, dispersible composition having stable dispersibility over time is provided. The composition exhibits a characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), wherein the difference between Tg and Ts is at least about 10° C. (i.e. Tg−Ts is greater than 10° C.). The composition comprises a mixture of a pharmaceutically-acceptable glassy matrix and at least one pharmacologically active material within the glassy matrix. It may be further mixed with a powdered, pharmaceutically-acceptable carrier. It is particularly valuable in unit dosage from having a moisture barrier, in combination with appropriate labelling instructions. A process for producing a powdered dispersible composition is also provided, wherein the process comprises removing the solvent from a solution comprising a solvent, a glass former and a pharmacologically active material under conditions sufficient to form a glassy matrix having the pharmacologically active material within the matrix.
An aerosolized powder composition for pulmonary administration that, prior to aerosolization, has been stored for a minimum period of 3 weeks at a storage temperature (Ts) that is at least 10° C. lower than the glass transition temperature (Tg) of said composition,
A process for maintaining the aerosol performance of a powder composition over time, said process comprising:
Dependencies are inferred from the claim text.